/home/grassnews/public_html/wp-content/themes/zox-news/parts/post-single.php on line 153
">
Warning: Undefined array key 0 in /home/grassnews/public_html/wp-content/themes/zox-news/parts/post-single.php on line 153
Warning: Attempt to read property "cat_name" on null in /home/grassnews/public_html/wp-content/themes/zox-news/parts/post-single.php on line 153
Dexcom and Companion Medical Announce Collaboration to Integrate Dexcom CGM Data and InPen™ Insulin Data
SAN DIEGO–(BUSINESS WIRE)–DexCom, Inc. (NASDAQ:DXCM) and Companion Medical, Inc. today announced a
collaboration to enable a direct exchange of CGM data from Dexcom with
insulin data from InPen into both companies’ software applications.
This agreement is the first of its kind and paves the way for advanced
diabetes decision support, an important tool for insulin users.
Dexcom and Companion Medical are working together to develop a seamless
data transfer of both insulin and glucose information. This
collaboration enables both companies to offer advanced features and
algorithms to improve in-the-moment decisions for those managing their
diabetes with multiple daily injections. Advanced decision support
requires multiple inputs, including current glucose, glucose trend,
carbohydrate intake, accurate insulin dosing and insulin-on-board.
“Dexcom is committed to helping people make better therapy decisions
based on their glucose levels, and Companion is committed to helping
people make better insulin dosing decisions. These decisions are
synchronous to the person living with diabetes which provides a
compelling opportunity for our teams to work together,” said Steve
Pacelli, EVP of Strategy and Corporate Development at Dexcom.
“We are pleased to be partnering with Dexcom on this important mission.
Improving outcomes for people on multiple daily injections requires
bringing together the two critical factors of diabetes management —
glucose and insulin — in real-time. We are the first two companies with
the technology capable of providing an integrated solution,” said Sean
Saint, CEO of Companion Medical.
As a first step in this collaboration, Dexcom and Companion Medical will
enable InPen users to display long-acting and rapid-acting insulin data
in the Dexcom CLARITY Diabetes Management Software. Dexcom CGM data is
currently available in the Companion Medical Insights by InPen report.
This integration enables health care providers to access a combined,
comprehensive view of a patient’s therapy plan, increasing the
effectiveness of how and when patients should dose and paving the way
for improved and transparent treatment decisions.
The InPen/CLARITY report integration will be launched and available for
preview at the upcoming American Diabetes Association Conference in San
Francisco. Both companies are actively developing their real-time
integrated systems.
About DexCom, Inc.
DexCom, Inc., headquartered in San Diego, CA, is dedicated to helping
people better manage their diabetes by developing and marketing
continuous glucose monitoring (CGM) products and tools for adult and
pediatric people with diabetes. With exceptional performance, comfort
and lifestyle flexibility at the heart of its technology, users have
consistently ranked DexCom highest in customer satisfaction and loyalty.
For more information on the Dexcom CGM, visit www.dexcom.com.
About Companion Medical, Inc.
Companion Medical is a leader in the development of advanced technology
to improve diabetes care. InPen, the first and only FDA-cleared smart
insulin pen, combines an innovative diabetes management app with a
Bluetooth® enabled pen injector to simplify the constant tracking,
monitoring and calculating required for insulin therapy. InPen addresses
many of the issues that people living with diabetes face on a daily
basis, including missed insulin doses, miscalculated insulin doses and
insulin stacking.
Contacts
Dexcom Investor Contact:
Steve Pacelli, 858-200-0200
Dexcom Press Contact:
James McIntosh, 619-884-2118
Companion Medical Media Contact:
Steve Lamar
[email protected]
(858)
522-0252
CompanionMedical.com
Warning: Undefined array key 0 in /home/grassnews/public_html/wp-content/themes/zox-news/parts/post-single.php on line 493
Warning: Attempt to read property "cat_ID" on null in /home/grassnews/public_html/wp-content/themes/zox-news/parts/post-single.php on line 493
Cannabis
Sannabis, Inc. (OTC: USPS) Announces First Shipment of Cannabis Essential Oil from Colombia to U.S. to Fill First Order, as the DEA Re-Classifies Marijuana from Schedule I to Schedule III
Humboldt
Humboldt Seed Company partners with Apollo Green to bring California cannabis genetics to the global marketplace
Apollo Green to distribute Humboldt Seed Company clonal cannabis genetics to Germany, Portugal and Australia
SAN FRANCISCO, April 30, 2024 /PRNewswire/ — Humboldt Seed Company (HSC), California’s leading cannabis seed producer, has announced a partnership with Canadian-based Apollo Green to make eight breeder cuts available to researchers, licensed commercial cultivators and home growers in legal markets worldwide. This first-to-market clonal genetics release is a significant milestone and will expand access to distinctive, high-quality cannabis genetics in both established and emerging global markets including Germany, Portugal and Australia.
The curated, breeder-verified selection includes pioneering triploid genetics, such as OG Triploid and Donutz Triploid alongside the legendary cult classic Blueberry Muffin. Also available are All Gas OG with a THC content of 21% and four high-THC strains in the 30-35% range: Golden Sands, Guzzlerz, Jelly Donutz and Orange Creampop. These selections represent the top .01% from HSC’s extensive California pheno-hunting program.
Exports will begin in May under Apollo Green’s Canadian federal cannabis license. All shipments have Canadian phytosanitary certification, ensuring plants have been inspected, and are clean and free of pests.
“Access for all to quality genetics has been our core focus since the beginning,” said HSC Co-founder and Chief Science Officer, Benjamin Lind. “Our science-based approach to breeding aligns perfectly with Apollo Green’s high standards and we are excited to be able to extend these hand-selected cuts to a wider audience, especially at this pivotal time where we’re seeing positive regulatory changes globally.”
Oisin Tierney, Apollo Green Director of Business Development, said, “California has long been recognized for setting industry standards, and we are proud to play a role in bringing these esteemed genetics to cultivators worldwide. The triploids are especially noteworthy in terms of the unprecedented potential for enhanced plant vigor, higher yields, shorter flowering times and superior returns for solventless extraction.”
About Humboldt Seed Company
Established in 2001, Humboldt Seed Company is a Northern California heritage brand providing quality cannabis genetics to commercial cultivators and home growers in legalized states across the U.S. and international markets including Spain, Canada, Jamaica, South Africa, Colombia, France, Portugal, Greece, the UK, Malta and Thailand. With a focus on environmental and social justice, they combine traditional breeding and modern scientific practices in their strain development program. They have served the cannabis community for over two decades.
For more information visit https://humboldtseedcompany.com/.
About Apollo Green
Licensed since 2019, Apollo Green is Canada’s leader in cannabis genetics. The company’s mission is to provide an ever-growing bank of seeds and clones to medical patients and recreational consumers. Apollo Green provides clean, trusted cannabis seeds and clones, which are backed by the foremost tissue culture technology to reduce risks, costs and time-to-market for licensed producers around the world. Apollo Green is passionate about cannabis genetics.
For more information visit https://apollogreen.com/.
Media contact
Jaana Prall
[email protected]
Logo – https://mma.prnewswire.com/media/2328955/Humboldt_Seed_Company_Logo.jpg
View original content:https://www.prnewswire.co.uk/news-releases/humboldt-seed-company-partners-with-apollo-green-to-bring-california-cannabis-genetics-to-the-global-marketplace-302131618.html
Cannabis
Technological Advancements in Breathalyzers Drive Market Growth and Enhance Road Safety
-
Innocan2 weeks ago
Innocan Pharma Initiates FDA Approval Process for Liposome Injection Therapy for Chronic Pain
-
Curaleaf2 weeks ago
Curaleaf Completes Acquisition of Northern Green Canada
-
Cannabis2 weeks ago
Cannabis Capsule Global Analysis Report 2024: Market to Reach $79.2 Billion in 2028 – Forecast to 2033 Featuring GW Pharmaceuticals, Trulieve Cannabis, Green Thumb Industries, Tilray, Columbia Care
-
Cannabis5 days ago
Technological Advancements in Breathalyzers Drive Market Growth and Enhance Road Safety
-
SCHWAZZE5 days ago
Schwazze Sets First Quarter 2024 Conference Call for May 15, 2024 at 5:00 p.m. ET
-
Cannabis5 days ago
Bay Area Social Equity Operator Launches the Purple Raina Balm Wand 1:1, an Inclusive Multipurpose Cannabis Topical
-
Humboldt5 days ago
Humboldt Seed Company partners with Apollo Green to bring California cannabis genetics to the global marketplace
-
Cannabis3 days ago
Sannabis, Inc. (OTC: USPS) Announces First Shipment of Cannabis Essential Oil from Colombia to U.S. to Fill First Order, as the DEA Re-Classifies Marijuana from Schedule I to Schedule III